A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Crytococcus neoformans infection

Journal of Immunology

Volumn 166, Issue 2, 2001, Pages 1087-1096

  Fleuridor, R ^a   Lees, A ^a   Pirofski, L A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MANNAN; PEPTIDE; POLYSACCHARIDE; TETANUS TOXOID; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONJUGATE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MYCOSIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0035863828     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.2.1087     Document Type: Article

References (58)

1. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City
2. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans
3. Human cryptococcosis
4. Therapy of cryptococcosis
5. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages
6. Antifungal activity of a human antiglucuronoxylomannan antibody
7. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide
8. Protection of mice against experimental cryptococcosis by an anti-Cryptococcus neoformans monoclonal antibody
9. Protective routine monoclonal antibodies to Cryptococcus neoformans
10. Cryptococcus neoformans: Paradigm for the role of antibody in immunity
11. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis
12. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies
13. T cell-independent antigens type 2
14. Efficacy of pneumococcal conjugate vaccines in large scale clinical trials
15. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children: Northern California Kaiser Permanente Vaccine Study Center Group
16. The 1996 Lasker Medical Research Awards: Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide vaccines
17. Preclinical efficacy of a ghicuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model
18. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection
19. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell
20. Dispute slows paper on "remarkable" vaccine
21. Isotype switching from IgG3 to IgG1 converts a nonprotective antibody routine antibody to Cryptococcus neoformans to a protective antibody
22. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan
23. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans
24. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody
25. Peptide mimicry of the meningococcal group C capsular polysaccharide
26. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library
27. Peptides that mimic the group B streptococcal type Ill capsular polysaccharide antigen
28. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine
29. Quantitative and qualitative differences in the serum antibody profiles of HIV-infected persons with and without Cryptococcus neoformans meningitis
30. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans
31. Picogram quantities of anti-Ig antibodies coupled to dextran induce B cell proliferation
32. Enhanced immunogenicity of protein-dextran conjugates. I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules
33. Conjugation to preadsorbed preactivated proteins and efficient generation of antipeptide antibodies
34. - individuals
35. Characterization of a marine monoclonal antibody to C. neoformans polysaccharide which is a candidate for human therapeutic studies
36. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide
37. Exploring the basis of peptide-carbohydrate crossreactivity: Evidence for discrimination by peptides between closely related anti-carbohydrate antibodies
38. Selection of an immunogenic and protective epitope of the PsaA protein of Streptococcus pneumoniae using a phage display library
39. Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines
40. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics
41. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningiditis serogroup B disease
42. Biochemistry
43. Immune responses to bacterial polysaccharides: Terminal epitopes are more immunogenic than internal structures
44. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination
45. In vivo polysaccharide-specific IgG isotype responses tO intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions
46. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae
47. Effect of carder priming on immunogenicity of saccharide-protein conjugate vaccines
48. Crossreactivity of mimotopes and peptide homologues of a sequential epitope with a monoclonal antibody does not predict crossreactive immunogenicity
49. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses
50. y immune responses in rabbits and mice
51. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2
52. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo
53. Protection against measles-virus reduced encephalitis by anti-mimitope antibodies: The role of antibody affinity
54. Variable efficacy of passive antibody administration against diverse Cryptococcus neofarmans strains
55. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide
56. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice
57. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans, glucuronoxylomannan alone and in combination with amphotericin B